| Shailesh J Patel, DO | |
|
2149 E Warner Rd Ste 102, Tempe, AZ 85284-3495 | |
| (480) 610-6100 | |
| (480) 610-0189 |
| Full Name | Shailesh J Patel |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 28 Years |
| Location | 2149 E Warner Rd Ste 102, Tempe, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144274861 | NPI | - | NPPES |
| 713413 | Medicaid | AZ | |
| 3740 | Other | AZ | ARIZONA STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 3740 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Del E. Webb Medical Center | Sun city west, AZ | Hospital |
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Kidney Institute Plc | 8224930987 | 81 |
News Archive
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, and ReDent Nova, a Tel Aviv-based dental company, have reached a new global agreement.
Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.
Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.
› Verified 8 days ago
| Entity Name | Southwest Kidney Institute Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659316008 PECOS PAC ID: 8224930987 Enrollment ID: O20040211001069 |
News Archive
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, and ReDent Nova, a Tel Aviv-based dental company, have reached a new global agreement.
Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.
Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.
› Verified 8 days ago
| Entity Name | Southwest Kidney Institute Scottsdale Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902231012 PECOS PAC ID: 3577798313 Enrollment ID: O20131101000457 |
News Archive
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, and ReDent Nova, a Tel Aviv-based dental company, have reached a new global agreement.
Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.
Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shailesh J Patel, DO 2149 E Warner Rd Ste 102, Tempe, AZ 85284-3495 Ph: (480) 610-6100 | Shailesh J Patel, DO 2149 E Warner Rd Ste 102, Tempe, AZ 85284-3495 Ph: (480) 610-6100 |
News Archive
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, and ReDent Nova, a Tel Aviv-based dental company, have reached a new global agreement.
Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.
Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine appropriate clopidogrel dosing and who had high residual platelet reactivity were at an increased risk of an ischemic event at short- and long-term follow-up of up to 2 years, according to a study in the September 21 issue of JAMA.
Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.
› Verified 8 days ago
Dr. Steven Alex Baldwin, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1898 E Southern Ave, Tempe, AZ 85282 Phone: 480-838-0068 Fax: 480-838-3409 | |
Denise I Beighe, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 451 E University Dr, Tempe, AZ 85281 Phone: 480-965-3346 Fax: 480-965-8914 | |
Dr. M. Jamil Akhtar, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2157 E Baseline Rd, Suite 101, Tempe, AZ 85283 Phone: 480-962-9494 Fax: 480-962-8140 | |
Emil Slovak Jr., M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4600 S Mill Ave, Suite 280, Tempe, AZ 85282 Phone: 480-305-2888 Fax: 480-305-2889 | |
Supriya Bhandari, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1840 E Broadway Rd, Tempe, AZ 85282 Phone: 602-243-7277 Fax: 480-927-1092 | |
Dr. Monaliza Setudehnia, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2055 E Southern Ave, Suite D, Tempe, AZ 85282 Phone: 480-345-7676 | |
Dr. Vanessa Joyce Tang, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1920 E Baseline Rd, Tempe, AZ 85283 Phone: 480-453-5000 Fax: 480-345-5266 |